Rebiotix is a clinical-stage biotechnology company revolutionizing the treatment of patients facing challenging GI diseases by harnessing the power of the human microbiome.
Location: United States, Minnesota, Roseville
Employees: 51-200
Total raised: $25M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | JVC Invest... | jvcmanagem... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.08.2014 | Series B | $25M | - |
Mentions in press and media 15
| Date | Title | Description |
| 30.11.2022 | FDA approves first fecal microbiome drug, setting stage for others | The Food and Drug Administration approved the first therapy using bacteria from stool samples to treat a bowel disorder on Wednesday, paving the way for several similar treatments in development. The drug, called Rebyota, is given as a one-... |
| 06.10.2021 | Vedanta Bio guts out microbiome trial win to keep up with field, get BARDA cash | The science of treating intestinal infections with a microbiome drug is progressing with at least four biotech companies developing such therapies, three of them in late-stage clinical trials. Vendanta Biosciences lags the group, but the bi... |
| 03.06.2021 | Gut therapy: MicrobiomX raises $1M for stool collection and processing device, analysis service | MicrobiomX’s device for stool collection also extrudes stool into capsules. (MicrobiomX Photo) New funding: MicrobiomX, a Seattle startup developing a device to collect and process stool samples for clinical use, has raised $1 million in a ... |
| 10.05.2020 | Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data | Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660. |
| 09.04.2018 | Sofia Fund Achieves Exit | Rebiotix, Inc., Announces Its Acquisition |
| 12.06.2017 | Seres initiates industry-first pivotal microbiome trial | Seres has long been a leader in the high-buzz microbiome field. In June 2015, it executed the industry’s first-ever initial public offering (IPO), raising an impressive $134 million. It also claimed the ticker symbol MCRB. But it’s not all ... |
| 03.08.2016 | How the microbiome will lead a revolution in the consumerization of personalized medicine and diet | Kobi Gershoni Contributor Kobi Gershoni is the co-founder and Chief Research Officer of Signals Analytics. Alexandra V. Eberhard Contributor Alexandra V. Eberhard is the executive VP of sciences at Signals Analytics and general manager of S... |
| 15.01.2015 | Medtech investment hits 6-year high in Minnesota | Investment in Minnesota’s thriving medtech scene hit a 6-year high in 2014 and the state saw a significant jump in pharma/biotech investments, according to LifeScience Alley’s annual report. The group’s "2014 Annual Report on Minnesota... |
| 04.08.2014 | Rebiotix Receives $25M for Series B | ROSEVILLE, MN, Rebiotix announced this morning that it has raised a total of $25 million in Series B Funding. >> Click here for more funding data on Rebiotix >> To export Rebiotix funding data to PDF and Excel, click here ... |
| 04.08.2014 | Fecal-transplant specialist Rebiotix nabs $25M round | Roseville, MN-based Rebiotix says it raised $25 million in a Series B, designed to fund pivotal work on its lead fecal-transplant program for RBX2660. RBX2660 is described as a non-antibiotic treatment under study for recurrent Clostridium ... |
Show more